Bioequivalence study of two favipiravir tablet formulations in healthy male subjects

The global pandemic called COVID-19 has dragged the world into a healthcare crisis, and favipiravir is one of the most prescribed agents against the virus so far. Favipiravir is a repurposed antiviral agent in treatment of SARS-CoV-2 infection, and to meet the current need, pharmaceutical companies...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of clinical pharmacology and therapeutics 2021-05, Vol.59 (5), p.409-416
Hauptverfasser:	Sağlam, Onursal, Güney, Berrak, Saraner, Nihal, Sevici, Gamze, Doğan-Kurtoğlu, Emel, Ulusoy, Merve G, Demiray, Gökçe, Nacak, Muradiye, Erenmemişoğlu, Aydın, Ozbek, Mahmut, Aytaç, Peri
Format:	Artikel
Sprache:	eng
Schlagworte:	Amides Antiviral Agents - therapeutic use Area Under Curve Bioequivalence Clinical trials Coronaviruses COVID-19 COVID-19 - drug therapy Cross-Over Studies Drug dosages Healthy Volunteers Humans Laboratories Male Males Medical equipment Pandemics Pharmaceutical industry Plasma Pyrazines SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Tablets Therapeutic Equivalency
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!